The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Atyr Pharma Inc. | Common Stock | 002120103 | 1,186 | 130,572 | SH | SOLE | 130,572 | 0 | 0 | ||
| Dare Bioscience, Inc. | Common Stock | 23666P101 | 545 | 326,240 | SH | SOLE | 326,240 | 0 | 0 | ||
| Genocea Biosciences, Inc. | Common Stock | 372427401 | 379 | 197,345 | SH | SOLE | 197,345 | 0 | 0 | ||
| Lyra Therapeutics, Inc. | Common Stock | 55234L105 | 10,044 | 1,100,852 | SH | SOLE | 1,100,852 | 0 | 0 | ||
| Pulmatrix, Inc. | Common Stock | 74584P202 | 288 | 359,441 | SH | SOLE | 359,441 | 0 | 0 | ||
| x4 Pharmaceuticals Inc. | Common Stock | 98420x103 | 1,648 | 311,492 | SH | SOLE | 311,492 | 0 | 0 | ||